Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial Meeting Abstract


Authors: O'Connor, O. A.; Masszi, T.; Savage, K. J.; Pinter-Brown, L. C.; Foss, F. M.; Popplewell, L.; Cashen, A. F.; Doorduijn, J.; Chawla, S.; Knoblauch, P.; Zinzani, P. L.; Brown, P.; Hess, G.; Van Hoof, A.; Horwitz, S. M.; Shustov, A. R.
Abstract Title: Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial
Meeting Title: 49th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 31
Issue: 15 Suppl.
Meeting Dates: 2013 May 31-Jun 4
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2013-05-20
Language: English
ACCESSION: WOS:000335419602603
PROVIDER: wos
Notes: Meeting Abstract: 8507 -- Source: Wos